Center for Environmentally
Beneficial Catalysis

  • Home
  • SABIC Americas joins CEBC as 21st industry partner

SABIC Americas joins CEBC as 21st industry partner

Tuesday, April 29, 2014

SABIC Americas is CEBC's 21st industry partner.  The company is a wholly-owned United States subsidiary of SABIC. It was incorporated in Delaware in 1987 with offices in Connecticut, and its commercial offices moved to Houston in 1998. Today, it manages sales, marketing, business development, manufacturing, and research and technology throughout the Americas.

SABIC is a leading provider of basic and intermediate chemicals and fertilizer products to industries throughout the USA, Canada, Mexico, Central America, South America and the Caribbean. SABIC Americas also operates its own Research and Technology Center in Sugar Land, Texas, a state-of-the-art petrochemical research facility, which enables it to stay at the cutting edge of scientific advances in the industry.



CEBC Calendar

September 13, Wednesday - Mandatory Lab Safety Meeting
All researchers at 1501 Wakarusa Dr. must attend

9:00 a.m. in Building B seminar room

September 19, Tuesday - CEBC Colloquium
Dr. David Sholl, Chair of Georgia Tech School of Chemical & Biomolecular Engineering
"New Nanoporous Materials for Practical Applications Using Computation Modeling - How Close Is the Dream to Reality?"

9:00 a.m. - 10:00 a.m., 1501 Wakarusa Drive, Building B seminar room
10:00 a.m. discussion with students

October 16 & 17, Monday & Tuesday - CEBC Fall Industry Advisory Board Meeting
Registration is Open - click here!

Monday 12:00-7:30 p.m. at the Adams Alumni Center, 1266 Oread Avenue, Lawrence
Tuesday 8:30-noon at the CEBC Complex, 1501 Wakarusa Drive, Lawrence

November 7, Tuesday - CEBC Industry Colloquium
Dr. Brandon Emme, Cellulose Team Leader, ICM, Inc.
"Title TBA"

9:00 a.m. - 10:00 a.m., 1501 Wakarusa Drive, Building B seminar room
10:00 a.m. discussion with students

KU Today
48 nationally ranked graduate programs.
—U.S. News & World Report
Pharmacy school No. 2 nationally for NIH funding